1. Smac mimetics and TRAIL cooperate to induce MLKL-dependent necroptosis in Burkitt's lymphoma cell lines
- Author
-
Sjoerd J L van Wijk, Simone Fulda, Birte Jeiler, Jens Roedig, Nadezda Dolgikh, and Annkathrin Koch
- Subjects
0301 basic medicine ,Cancer Research ,TBZ, TRAIL/BV6/zVAD.fmk ,TNFR1, tumor necrosis factor receptor 1 ,TRAIL ,Nec-1s, Necrostatin-1s ,Ligands ,TNF-Related Apoptosis-Inducing Ligand ,0302 clinical medicine ,MLKL, mixed lineage kinase domain-like protein ,Blast, Blasticidin ,n.h.t, non-human target ,CRISPR ,FASR, FAS receptor ,RIP, receptor interacting protein ,cIAP, cellular inhibitor of apoptosis ,Caspase ,RC254-282 ,Original Research ,Gene knockdown ,biology ,Cell Death ,Burkitt's lymphoma ,Biological Mimicry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Methylation ,Burkitt Lymphoma ,Gene Expression Regulation, Neoplastic ,CRISPR, clustered regularly interspaced short palindromic repeats ,PBMC, peripheral blood mononuclear cells ,030220 oncology & carcinogenesis ,Necroptosis ,RNA Interference ,Smac mimetics ,Disease Susceptibility ,TRAIL-R2, TRAIL receptor 2 ,Oligopeptides ,MLKL ,TNFα, tumor necrosis factor alpha ,BL, Burkitt's lymphoma ,Puro, Puromycin ,SEM, standard error of the mean ,TRAIL-R1, TRAIL receptor 1 ,Mitochondrial Proteins ,PI, propidium iodide ,03 medical and health sciences ,Cell Line, Tumor ,RIPK1/3, receptor interacting serine/threonine kinase 1/3 ,TRAIL, tumor necrosis factor-related apoptosis-inducing ligand ,medicine ,Humans ,FASL, FAS ligand ,zVAD.fmk, N-benzyloxycarbonyl-Val-Ala-Asp(O–Me) fluoromethylketone ,KD, knockdown ,EV, empty vector ,KO, knockout ,IAP, inhibitor of apoptosis ,NSA, Necrosulfonamide ,medicine.disease ,Lymphoma ,DNMT, DNA-methyltransferase ,030104 developmental biology ,Cell culture ,Cancer research ,biology.protein ,DOX, doxycycline hydrochloride ,FCS, fetal calf serum ,Apoptosis Regulatory Proteins ,Protein Kinases ,OE, overexpression - Abstract
Burkitt's lymphoma (BL) is a highly aggressive form of B-cell non-Hodgkin's lymphoma. The clinical outcome in children with BL has improved over the last years but the prognosis for adults is still poor, highlighting the need for novel treatment strategies. Here, we report that the combinational treatment with the Smac mimetic BV6 and TRAIL triggers necroptosis in BL when caspases are blocked by zVAD.fmk (TBZ treatment). The sensitivity of BL cells to TBZ correlates with MLKL expression. We demonstrate that necroptotic signaling critically depends on MLKL, since siRNA-induced knockdown and CRISPR/Cas9-mediated knockout of MLKL profoundly protect BL cells from TBZ-induced necroptosis. Conversely, MLKL overexpression in cell lines expressing low levels of MLKL leads to necroptosis induction, which can be rescued by pharmacological inhibitors, highlighting the important role of MLKL for necroptosis execution. Importantly, the methylation status analysis of the MLKL promoter reveals a correlation between methylation and MLKL expression. Thus, MLKL is epigenetically regulated in BL and might serve as a prognostic marker for treatment success of necroptosis-based therapies. These findings have crucial implications for the development of new treatment options for BL., Graphical Abstract Image, graphical abstract
- Published
- 2021